Park Hanul, Park Young Joon, Lee Hye Young, Yu Mi, Song Yeong-Jun, Lee Sang Eun, Lee Ji-Joo, Lee Eun-Sol, Kim Yeonjung
Division of Epidemiological Investigation Analysis, Korea Disease Control and Prevention Agency, Cheongju, Korea.
Division of Infectious Disease Response, Gyeongnam Reginal Center for Disease Control and Prevention, Korea Disease Control and Prevention Agency, Busan, Korea.
Osong Public Health Res Perspect. 2022 Dec;13(6):443-447. doi: 10.24171/j.phrp.2022.0262. Epub 2022 Dec 23.
On November 5, 2021, Pfizer Inc. announced Paxlovid (nirmatrelvir +ritonavir) asa treatment method that could reduce the risk of hospitalization or death for patients withconfirmed coronavirus disease 2019 (COVID-19).
From February 6, 2022 to April 2, 2022, the incidence of COVID-19 and the effectsof treatment with Paxlovid were analyzed in 2,241 patients and workers at 5 long-term carefacilities during the outbreak of the Omicron variant of severe acute respiratory syndromecoronavirus 2 in South Korea.
The rate of severe illness or death in the group given Paxlovid was 51% lower thanthat of the non-Paxlovid group (adjusted risk ratio [aRR], 0.49; 95% confidence interval [CI],0.24-0.98). Compared to unvaccinated patients, patients who had completed 3 doses of thevaccine had a 71% reduced rate of severe illness or death (aRR, 0.29; 95% CI, 0.13-0.64) and a65% reduced death rate (aRR, 0.35; 95% CI, 0.15-0.79).
Patients given Paxlovid showed a lower rate of severe illness or death and alower fatality rate than those who did not receive Paxlovid. Patients who received 3 dosesof the vaccine had a lower rate of severe illness or death and a lower fatality rate than theunvaccinated group.
2021年11月5日，辉瑞公司宣布帕罗韦德（奈玛特韦+利托那韦）作为一种治疗方法，可降低确诊的2019冠状病毒病（COVID-19）患者住院或死亡风险。
2022年2月6日至2022年4月2日，在韩国严重急性呼吸综合征冠状病毒2奥密克戎变种爆发期间，对5家长期护理机构的2241名患者和工作人员的COVID-19发病率及帕罗韦德治疗效果进行了分析。
接受帕罗韦德治疗组的重症或死亡率比未接受帕罗韦德治疗组低51%（调整风险比[aRR]，0.49；95%置信区间[CI]，0.24-0.98）。与未接种疫苗的患者相比，完成3剂疫苗接种的患者重症或死亡率降低了71%（aRR，0.29；95%CI，0.13-0.64），死亡率降低了65%（aRR，0.35；95%CI，0.15-0.79）。
接受帕罗韦德治疗的患者与未接受帕罗韦德治疗的患者相比，重症或死亡率较低，病死率也较低。接种3剂疫苗的患者与未接种疫苗的患者相比，重症或死亡率较低，病死率也较低。
